146 related articles for article (PubMed ID: 25481459)
1. Relevance of various animal models of human infections to establish therapeutic equivalence of a generic product of piperacillin/tazobactam.
Agudelo M; Rodriguez CA; Zuluaga AF; Vesga O
Int J Antimicrob Agents; 2015 Feb; 45(2):161-7. PubMed ID: 25481459
[TBL] [Abstract][Full Text] [Related]
2. In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products.
Rodriguez CA; Agudelo M; Zuluaga AF; Vesga O
Int J Antimicrob Agents; 2017 Feb; 49(2):189-197. PubMed ID: 27988068
[TBL] [Abstract][Full Text] [Related]
3. Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam.
Rodriguez CA; Agudelo M; Aguilar YA; Zuluaga AF; Vesga O
PLoS One; 2016; 11(5):e0155806. PubMed ID: 27191163
[TBL] [Abstract][Full Text] [Related]
4. More potency assay results for generic non-USA lots of piperacillin/tazobactam and initial reports for generic meropenem compounds marketed in the USA.
Jones RN; Sader HS; Flamm RK; Watters AA
Diagn Microbiol Infect Dis; 2013 May; 76(1):110-2. PubMed ID: 23490010
[TBL] [Abstract][Full Text] [Related]
5. Microbiological equivalence of bacteriostatic and bactericidal activities of the sera from healthy volunteers receiving generic piperacillin/tazobactam (Pipertaz) and original piperacillin/tazobactam (Tazocin).
Thamlikitkul V; Tiengrim S; Chalermsri C; Sae-Jong R; Suddhichupaiboon S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S196-202. PubMed ID: 21721447
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae.
Harada Y; Morinaga Y; Kaku N; Nakamura S; Uno N; Hasegawa H; Izumikawa K; Kohno S; Yanagihara K
Clin Microbiol Infect; 2014 Nov; 20(11):O831-9. PubMed ID: 24813594
[TBL] [Abstract][Full Text] [Related]
7. In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa.
Hyatt JM; Nix DE; Stratton CW; Schentag JJ
Antimicrob Agents Chemother; 1995 Aug; 39(8):1711-6. PubMed ID: 7486906
[TBL] [Abstract][Full Text] [Related]
8. Influence of culture site-specific MIC distributions on the pharmacokinetic and pharmacodynamic properties of piperacillin/tazobactam and piperacillin: a data analysis.
Frei CR; Hampton SL; Burgess DS
Clin Ther; 2006 Jul; 28(7):1035-40. PubMed ID: 16990081
[TBL] [Abstract][Full Text] [Related]
9. Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin.
Agudelo M; Rodriguez CA; Zuluaga AF; Vesga O
PLoS One; 2019; 14(2):e0211096. PubMed ID: 30726248
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
Butterfield JM; Lodise TP; Beegle S; Rosen J; Farkas J; Pai MP
J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
[TBL] [Abstract][Full Text] [Related]
11. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator.
Vesga O; Agudelo M; Salazar BE; Rodriguez CA; Zuluaga AF
Antimicrob Agents Chemother; 2010 Aug; 54(8):3271-9. PubMed ID: 20547818
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic equivalence requires pharmaceutical, pharmacokinetic, and pharmacodynamic identities: true bioequivalence of a generic product of intravenous metronidazole.
Agudelo M; Vesga O
Antimicrob Agents Chemother; 2012 May; 56(5):2659-65. PubMed ID: 22330928
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin.
Rodriguez CA; Agudelo M; Zuluaga AF; Vesga O
BMC Infect Dis; 2010 Jun; 10():153. PubMed ID: 20525378
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic evaluation of piperacillin-tazobactam.
Hayashi Y; Roberts JA; Paterson DL; Lipman J
Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):1017-31. PubMed ID: 20636224
[TBL] [Abstract][Full Text] [Related]
15. Serum bactericidal activity of piperacillin/tazobactam against Staphylococcus aureus, piperacillin-susceptible and piperacillin-resistant Escherichia coli and Pseudomonas aeruginosa.
Lemmen SW; Zolldann D; Klik S; Lütticken R; Kümmerer K; Häfner H
Chemotherapy; 2004 Apr; 50(1):27-30. PubMed ID: 15084802
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.
Occhipinti DJ; Pendland SL; Schoonover LL; Rypins EB; Danziger LH; Rodvold KA
Antimicrob Agents Chemother; 1997 Nov; 41(11):2511-7. PubMed ID: 9371358
[TBL] [Abstract][Full Text] [Related]
17. In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation.
Jones RN; Fritsche TR; Moet GJ
Diagn Microbiol Infect Dis; 2008 May; 61(1):76-9. PubMed ID: 18221852
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection.
Strayer AH; Gilbert DH; Pivarnik P; Medeiros AA; Zinner SH; Dudley MN
Antimicrob Agents Chemother; 1994 Oct; 38(10):2351-6. PubMed ID: 7840569
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
Li C; Kuti JL; Nightingale CH; Mansfield DL; Dana A; Nicolau DP
J Antimicrob Chemother; 2005 Aug; 56(2):388-95. PubMed ID: 16002420
[TBL] [Abstract][Full Text] [Related]
20. Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients.
Shea KM; Cheatham SC; Wack MF; Smith DW; Sowinski KM; Kays MB
Int J Antimicrob Agents; 2009 Nov; 34(5):429-33. PubMed ID: 19726163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
